Stay updated on BBI503 Combo with Anti-Cancer Agents Clinical Trial
Sign up to get notified when there's something new on the BBI503 Combo with Anti-Cancer Agents Clinical Trial page.

Latest updates to the BBI503 Combo with Anti-Cancer Agents Clinical Trial page
- CheckyesterdayChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been pushed back from June 2025 to July 2025.SummaryDifference0.8%
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check23 days agoChange DetectedThe web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference1%
- Check51 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check65 days agoChange DetectedThe page has undergone significant content changes, including the removal of detailed study descriptions and major inclusion/exclusion criteria for a clinical trial involving BBI503 and various anti-cancer drugs. New drug names such as Nivolumab and Pembrolizumab have been added, indicating a shift in focus towards specific treatments.SummaryDifference35%
- Check73 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
Stay in the know with updates to BBI503 Combo with Anti-Cancer Agents Clinical Trial
Enter your email address, and we'll notify you when there's something new on the BBI503 Combo with Anti-Cancer Agents Clinical Trial page.